ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0864

Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study

Kristine Godziuk1, Sarah Tilley2, mike LaValley3, Michael Nevitt4, C.E. Lewis5, James Torner6 and Tuhina Neogi2, 1University of Alberta, Edmonton, AB, Canada, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Boston University School of Public Health, Arlington, MA, 4UCSF, Orinda, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6University of Iowa, Iowa City

Meeting: ACR Convergence 2024

Keywords: Comorbidity, functional status, longitudinal studies, obesity, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Osteoarthritis – Novel Insights from Observational Studies

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people with obesity. It is possible that those with concurrent low muscle mass [i.e. sarcopenic obesity (SO)], or metabolic-related comorbidities but without low muscle [i.e. clinical comorbid obesity (CCO)] may have worse functional outcomes than those without either [i.e. uncomplicated or normal obesity (NO)]. Understanding if these distinct obesity subtypes contribute differentially to patterns of functional deterioration is needed to support targeted OA prevention and treatment strategies. We examined the relationship between obesity subtypes and trajectories of functional change after a 7-year follow-up period.

Methods: Participants from the Multicenter Osteoarthritis Study (MOST), a NIH-funded longitudinal cohort of individuals with or at-risk for knee OA, with a BMI ≥30 kg/m2 and baseline body composition data from DXA were included. The SO group had low muscle mass [appendicular lean soft tissue adjusted for weight] and high percent fat mass, defined by age and sex-specific cutpoints. The CCO group had metabolic comorbidities [self-reported diabetes, heart, liver, or pulmonary disease from the Charlson Comorbidity Index] but no low muscle. The NO group met neither SO or CCO definitions. Self-reported physical functioning was measured with WOMAC. Longitudinal patterns of physical function over 7-years were identified using a group-based trajectory model, with best-fit determined by low BIC and AIC, and high posterior probability of group membership. The relationship between obesity subtypes and trajectory group membership was examined using multinomial logistic regression.

Results: We included 1211 individuals (63% female, mean age 61.2±7.6 years, BMI 35.0±4.5 kg/m2). Compared to the NO group, both SO and CCO groups had worse physical function at baseline (Table 1). We identified 5 trajectories (TRAJ) of functional change over 7-years (Figure 1). Four of the five TRAJ reflected stable but distinct levels of functioning across 7-years, with TRAJ 3 and 5 having persistent poorer function. One group (TRAJ 4) demonstrated an improvement in WOMAC function during follow-up; group members were older and had higher rates of arthroplasty over follow-up than other TRAJ groups (Figure 2). A greater proportion of individuals in the persistent poorer function trajectory groups (TRAJ 3 and 5) were Black, had lower rates of post-secondary education, and higher rates of severe knee OA and a BMI ≥40 kg/m2 (Figure 2). The CCO group had higher odds of being in TRAJ 3, 4, and 5 [OR 2.1, 2.8, 2.5, respectively] than TRAJ 2 compared with the NO group. The SO group had higher odds of being in TRAJ 5 [OR 2.1], the worst function group.

Conclusion: Individuals with obesity and concurrent low muscle mass or metabolic comorbidities have persistent, worse impairments in functional status over a 7-year period compared to those with obesity alone. Distinguishing these obesity subtypes through body composition and comorbidity assessments may be needed to enable personalized intervention and to avoid extended mobility disability.

Supporting image 1

Table 1. Obesity subtypes and physical functioning at baseline (N=1211)

Supporting image 2

Figure 1. Five trajectories of functional change over a 7-year period in 1211 individuals with a body mass index ≥30kg/m2

Supporting image 3

Figure 2. Characteristics of individuals in the five trajectory groups


Disclosures: K. Godziuk: None; S. Tilley: None; m. LaValley: None; M. Nevitt: None; C. Lewis: None; J. Torner: None; T. Neogi: Amgen, 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, Sobi, 2.

To cite this abstract in AMA style:

Godziuk K, Tilley S, LaValley m, Nevitt M, Lewis C, Torner J, Neogi T. Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/obesity-subtypes-and-trajectories-of-functional-change-after-7-years-of-follow-up-the-multicenter-osteoarthritis-most-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-subtypes-and-trajectories-of-functional-change-after-7-years-of-follow-up-the-multicenter-osteoarthritis-most-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology